MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
IRIDEX Corporation Cost of Revenue 2011-2025 | IRIX
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue IRIDEX Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30.1 M | 31.6 M | 20.8 M | - | 25.5 M | 25.1 M | 26.1 M | 25.3 M | 21.4 M | - | 19.7 M | 17.5 M | 16.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 31.6 M | 16.9 M | 23.6 M |
Quarterly Cost of Revenue IRIDEX Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.47 M | 8.89 M | 6.84 M | - | 7.26 M | 7.5 M | 7.3 M | - | 7.23 M | 7.49 M | 7.77 M | - | 8.18 M | 7.49 M | 7.41 M | - | 7.48 M | 7.32 M | 7.02 M | - | 5.15 M | 3.81 M | 5.1 M | - | 6.38 M | 5.88 M | 6.34 M | - | 6.74 M | 6.04 M | 5.59 M | 8.07 M | 6.49 M | 5.51 M | 6.02 M | 6.97 M | 5.54 M | 6.17 M | 6.63 M | - | 4.97 M | 4.82 M | 5.39 M | - | 4.97 M | 5.29 M | 5.27 M | - | 4.8 M | 4.73 M | 4.71 M | - | 3.97 M | 4.33 M | 4.32 M | - | 4.27 M | 4.15 M | 4.11 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.89 M | 3.81 M | 6.09 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Abiomed
ABMD
|
162 M | - | - | $ 17.2 B |  USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Boston Scientific Corporation
BSX
|
5.26 B | $ 96.13 | 0.04 % | $ 141 B | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Apyx Medical Corporation
APYX
|
18.6 M | $ 3.6 | - | $ 125 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Bio-Rad Laboratories
BIO
|
1.19 B | $ 301.75 | 0.24 % | $ 8.51 B | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 48.12 | 0.21 % | $ 7.17 K | USA |
 |
Abbott Laboratories
ABT
|
18.7 B | $ 124.81 | 0.22 % | $ 217 B | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 2.97 | 4.58 % | $ 111 M |  France |
 |
IRadimed Corporation
IRMD
|
16.9 M | $ 97.06 | 0.48 % | $ 1.23 B | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
LivaNova PLC
LIVN
|
383 M | $ 63.08 | -0.27 % | $ 3.42 B |  Britain |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Cognyte Software Ltd.
CGNT
|
104 M | $ 9.54 | - | $ 685 M |  Israel |
 |
InMode Ltd.
INMD
|
77.8 M | $ 14.47 | 0.7 % | $ 1.15 B | Israel |
 |
Second Sight Medical Products
EYES
|
11.8 M | - | -0.97 % | $ 54.4 M | USA |
 |
Align Technology
ALGN
|
1.2 B | $ 157.84 | 0.69 % | $ 11.8 B | USA |
 |
Myomo
MYO
|
5.3 M | $ 1.02 | 12.09 % | $ 7.19 M | USA |
 |
NanoVibronix
NAOV
|
1.05 M | - | - | $ 1.08 M | USA |
 |
Accuray Incorporated
ARAY
|
312 M | $ 0.86 | 0.43 % | $ 88.4 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
ClearPoint Neuro
CLPT
|
12.3 M | $ 14.49 | 0.84 % | $ 392 M | USA |
|
LENSAR
LNSR
|
27.6 M | $ 12.01 | -0.08 % | $ 138 M | USA |
 |
AxoGen
AXGN
|
45.4 M | $ 32.64 | -0.61 % | $ 1.44 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
CONMED Corporation
CNMD
|
574 M | $ 40.17 | 1.34 % | $ 1.24 B | USA |
 |
NuVasive
NUVA
|
337 M | - | - | $ 2.07 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
56.1 M | $ 17.41 | 0.75 % | $ 402 M | USA |
 |
Globus Medical
GMED
|
1.04 B | $ 88.43 | -0.38 % | $ 12 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
728 M | $ 12.66 | 0.56 % | $ 975 M | USA |